New Tools Needed To Spread Word On Comparative Research Findings
This article was originally published in The Gray Sheet
Executive Summary
New tools are needed to ensure patients and doctors can make sense of the increasing volume of comparative effectiveness research expected out in coming years, policy experts suggest in recent papers in Health Affairs.
You may also be interested in...
AdvaMed Encourages HHS CER Inventory Efforts; Drug Groups Press For Delay
AdvaMed is encouraging Health and Human Services' efforts to start building a centralized inventory of comparative effectiveness research, even as drug industry groups complain the project would be "premature" before a congressionally established public-private institute gets up and running
Supporters Stress Consumer-Friendly Approach To Comparative Effectiveness
Debates are intensifying over how data resulting from government-supported comparative effectiveness studies should be applied
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”